ACM
CATX icon

ADAR1 Capital Management’s Perspective Therapeutics CATX Stock Holding History

ADAR1 Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Buy
1,210,117
+460,782
+61% +$1.74M 0.19% 109
2026
Q1 		$3.12M Buy
749,335
+654,142
+687% +$2.76M 0.18% 105
2025
Q4 		$262K Buy
+95,193
New +$272K 0.02% 216
2024
Q3 		– Sell
-69,985
Closed -$698K – 293
2024
Q2 		$698K Buy
69,985
+2,312
+3% +$33.4K 0.13% 82
2024
Q1 		$805K Buy
67,673
+63,453
+1,504% +$541K 0.18% 67
2023
Q4 		$17K Buy
+4,220
New +$11.9K 0.01% 132

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

ADAR1 Capital Management's CATX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Perspective Therapeutics (CATX) stake by 61% in Q2 2026, buying an estimated $1.74M and bringing the position to 1,210,117 shares worth $4.13M. The position accounts for 0.19% of the portfolio, ranked #109.

ADAR1 Capital Management first reported a position in CATX in Q4 2023 and has held it in 6 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • ADAR1 Capital Management held 1,210,117 shares of Perspective Therapeutics worth $4.13M as of Q2 2026.
  • ADAR1 Capital Management bought 460,782 Perspective Therapeutics shares in Q2 2026, an estimated $1.74M.
  • Perspective Therapeutics made up 0.19% of ADAR1 Capital Management's portfolio in Q2 2026, its #109 holding.
  • ADAR1 Capital Management first reported a position in Perspective Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.